Compare Abbott Laboratories (ABT) vs Walt Disney Co (DIS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Walt Disney Co — how do they compare? Abbott Laboratories trades at $95.23 (market cap $166.94B), while Walt Disney Co trades at $97.39 (market cap $169.28B). The key difference: Abbott Laboratories and Walt Disney Co are close in size by market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | DIS | |
|---|---|---|
Market Cap | $166.94B | $169.28B |
Sector | Health | Media |
52-Week High | $136.62 | $122.94 |
52-Week Low | $82.57 | $92.40 |
Enterprise Value | $193.69B | $210.95B |
Dividend Yield | 2.63% | 1.54% |
Volume | — | 7,546,013 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Disney (DIS) trades at $97.41, down 2.06% on the day, with a bearish technical signal despite strong fundamentals. The company has beaten earnings expectations for three consecutive quarters, with Q2 2026 EPS expected at $1.88. Revenue growth has accelerated from $82.7B in 2022 to $94.4B in 2025, while net income surged to $12.4B. Analyst consensus remains strongly bullish with a $131.89 price target, representing 35% upside potential from current levels.
Disney presents a compelling investment case with improving profitability and strong cash flow generation, though regulatory challenges and recent box office disappointments pose near-term risks. The stock's current valuation at 15.59x P/E appears attractive relative to growth prospects, while technical indicators suggest potential support near $94-96 levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Walt Disney Co
The Walt Disney Company is an entertainment company with operations in media networks, park experiences & consumer products, studio entertainment and Direct-to-Consumer networks and channels. The Company serves customers worldwide.
Read more on DIS →
